Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors

NCT00003515 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Primitive Neuroectodermal Tumor

Interventions

DRUG: Antineoplaston therapy (Atengenal + Astugenal)

Sponsor

Burzynski Research Institute